Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Histone deacetylase Stories

2011-10-24 14:20:00

MALVERN, Pa., Oct. 24, 2011 /PRNewswire/ -- Reaction Biology Corporation ("RBC"), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source. The enzymes offered for sale are active and validated for use...

2011-06-27 07:30:00

WALTHAM, Mass., June 27, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that data from two entinostat clinical trials both based on tumor reprogramming will be presented at the International Association for the Study of Lung Cancer's (IASLC) 14th World Conference on Lung Cancer meeting (www.2011worldlungcancer.org) July 3 to 7 in Amsterdam, The Netherlands. "The data presentations from both lung cancer programs at the...

2011-06-02 07:30:00

WALTHAM, Mass., June 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL--AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B." This follows the UK issuance which was granted in October of 2010 adding to the extensive patent estate. The patent covers the novel polymorph...

2011-05-31 13:32:58

A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found. The drug, a type of histone deacetylase (HDAC) inhibitor being evaluated in numerous ongoing clinical trials, has been shown to reverse the harmful effects of autophagy in heart muscle cells of mice. Autophagy is a natural process by which cells eat their own proteins to provide needed resources in times of stress. The new...

2011-05-04 06:00:00

SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009. As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx. Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently. Recent data...

2011-04-26 05:00:00

SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009. Over the past two years Servier has engaged in several exploratory Phase I/II trials in solid tumors and hematologic malignancies. Servier is now focused on its...

2011-04-15 00:00:28

BellBrook Labs has developed a new HTS assay for screening methyltransferases, the family of enzymes involved in epigenetic modifications that cause cancerous cell growth and metastasis. The innovative EPIGEN Methyltransferase Assay combines proprietary coupling enzymes with the detection module of the extensively validated Transcreener® HTS Assay platform to advance the discovery of new anti-cancer therapeutics. Madison, WI (PRWEB) April 14, 2011 BellBrook Labs today introduced an...

2011-04-05 14:53:42

Tumor suppressor genes normally control the growth of cells, but cancer can spring up when these genes are silenced by certain chemical reactions that modify chromosomes. Among the most common culprits responsible for inactivating these genes are histone deacetylases, a class of enzymes that remove acetyl groups from DNA-scaffolding proteins, and DNA methyltransferases, a family of enzymes that add methyl groups to DNA. Drugs that counteract these enzymes, and thus reactivate tumor suppressor...

2011-04-04 08:06:28

(Ivanhoe Newswire) -- Scientists have achieved one of the oldest and most rarely achieved goals of cancer research"”they have found a way to "distract" cancer cells from their normal activities and make them act like normal cells. The scientists, from Dana-Farber Cancer Institute and Brigham and Women's Hospital, managed to distract the cancer cells of a rare form of cancer called NUT midline carcinoma (NMC) that usually affects children and young adults. NMC is lethal; according to...

2011-03-31 07:30:00

WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL. "The breadth of exciting data being presented at AACR provides additional insight into the opportunities for Syndax to build out...